The viral latent reservoir is the major barrier to the development of an HIV cure. We previously found that virally suppressed, SIV-infected rhesus macaques treated with the combination of a toll-like receptor 7 (TLR7) agonist and Ad26/MVA vaccination had an increased incidence of virologic control and lower viral loads upon discontinuation of antiretroviral therapy (ART). SHIV-infected macaques treated with TLR7 agonist vesatolimod (VES) and neutralizing Ab PGT121 while on ART also had a lower frequency of and longer time to viral rebound compared to sham. We here treated ART-suppressed, SHIV-SF162P3-infected macaques with Ad26/MVA vaccination, PGT121, and VES, to determine if the combination of the three treatments resulted in outcomes improved from either set of two alone.
Macaques were challenged with SHIV-SF162P3 and initiated ART on day 9 of infection. The animals were sorted into treatment groups as follows: 1) Ad26/MVA vaccination and PGT121 and VES administration (n = 10), 2) Ad26/MVA vaccination and VES administration (n = 12), 3) PGT121 and VES administration (n = 12), or 4) sham treatment. Animals in groups 1-3 were given orally administered VES (0.15 mg/kg) ten times total, once every two weeks from weeks 50-58 and 64-72. Groups 1 and 3 were given five doses of 10 mg/kg PGT121 intravenously once every two weeks, starting at week 64. Groups 1 and 2 were vaccinated intramuscularly with Ad26 vectors at weeks 24 and 36 and boosted with MVA vectors at weeks 48 and 60. ART was discontinued at week 86 of infection to allow for PGT121 wash-out, and animals were followed for an additional 168 days.
Upon ART discontinuation, 70% of the animals treated with vaccination, PGT121, and VES either did not rebound or gained virologic control within the follow-up period, compared to 33% in the vaccination and VES group and 42% in the PGT121 and VES group. All three treatment groups had a significantly lower set-point viral load than sham (p < 0.001), and the two groups treated with PGT121 had a significantly lower likelihood of rebound (p < 0.0001).
Our data show that the combination of innate immune stimulation, bNAb administration, and therapeutic vaccination delays rebound and induces immune-mediated virologic control in SHIV-infected macaques upon discontinuation of ART. Using a combination of treatments targeting multiple mechanisms to induce control or prevent rebound is a promising strategy towards establishing a functional cure of HIV-1 infection.